A5062120456- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Bone health and treatments
- Cancer Immunotherapy and Biomarkers
- Tissue Engineering and Regenerative Medicine
- Prostate Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Management of metastatic bone disease
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Immune cells in cancer
- Renal and related cancers
- Bone health and osteoporosis research
- Hormonal and reproductive studies
- Testicular diseases and treatments
- Urological Disorders and Treatments
- Spine and Intervertebral Disc Pathology
- vaccines and immunoinformatics approaches
- Single-cell and spatial transcriptomics
Massachusetts General Hospital
2016-2025
Harvard University
2014-2025
Global Cancer Institute
2021
Dana-Farber Cancer Institute
2013-2020
MGH Institute of Health Professions
2020
Brigham and Women's Hospital
2019
University of Maryland, Baltimore
2014
University of Chicago
2014
Cancer Research Foundation
2014
University of California, Los Angeles
2013
Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it the most common solid tumor in men between ages 20 34 years, global incidence has been steadily rising over past several decades. Several risk factors testicular have identified, including personal or family history cryptorchidism. germ cell tumors (GCTs) comprise 95% malignant arising testes are categorized into 2 main histologic subtypes: seminoma nonseminoma. Although nonseminoma more clinically...
Purpose Zoledronic acid decreases the risk for skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases but its role earlier natural history of disease is unknown. This phase III study evaluated efficacy safety treatment zoledronic castration-sensitive metastatic cancer. Patients Methods Men whose androgen-deprivation therapy was initiated within 6 months entry were randomly assigned a blinded 1:1 ratio to receive (4 mg intravenously every 4 weeks)...
Increasing prevalence of metastatic disease has been accompanied by increasing rates surgical intervention. Current tools have poor to fair predictive performance for intermediate (90-d) and long-term (1-yr) mortality.To develop algorithms spinal at these time points provide patient-specific explanations the predictions generated algorithms.Retrospective review was conducted 2 large academic medical centers identify patients undergoing initial operative management between January 2000...
The treatment of low-risk primary prostate cancer entails active surveillance only, while high-risk disease requires multimodal including surgery, radiation therapy, and hormonal therapy. Recurrence development metastatic remains a clinical problem, without clear understanding what drives immune escape tumor progression. Here, we comprehensively describe the microenvironment localized in comparison with adjacent normal samples healthy controls. Single-cell RNA sequencing high-resolution...
Abstract Background Despite therapeutic advances, once a cancer has metastasized to the bone, it represents highly morbid and lethal disease. One third of patients with advanced clear cell renal carcinoma (ccRCC) present bone metastasis at time diagnosis. However, metastatic niche in humans, including immune stromal microenvironments, not been well-defined, hindering progress towards identification targets. Methods We collected fresh patient samples performed single-cell transcriptomic...
Purpose Fluorouracil plus cisplatin and radiation twice a day (FCT) is an established chemoradiation (CRT) regimen for selective bladder-sparing treatment of muscle-invasive bladder cancer. Gemcitabine once daily (GD) well-supported alternative. The current trial evaluates these regimens. Methods Patients with cT2-4a cancer were randomly assigned to FCT or GD. underwent transurethral resection induction CRT 40 Gy. who achieved complete response (CR) received consolidation 64 Gy others...
To report a multi-institutional case series of patients with advanced microsatellite instability high (MSI-H) prostate adenocarcinoma identified clinical cell-free DNA (cfDNA) next-generation sequencing (NGS) testing and treated immune checkpoint inhibitors. Retrospective analysis metastatic castration-resistant cancer (mCRPC) MSI-H tumor detected by commercially available cfDNA NGS assay Guardant360 (G360, Guardant Health) at eight different Academic Institutions in the USA, from September...
354 Background: Patients (pts) with mUC who progress after platinum (PLT)-based chemotherapy and immune checkpoint inhibitor (CPI) therapy have poor outcomes limited treatment options. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate. It consists of monoclonal antibody targeting Trop-2, an epithelial cell surface antigen overexpressed in UC, conjugated to the active metabolite irinotecan (SN38). Methods: We performed phase I/II basket study pts advanced solid tumors receiving...
Abstract Clear cell renal carcinoma (ccRCC) is the most common type of kidney cancer in adults. When ccRCC localized to kidney, surgical resection or ablation tumor often curative. However, metastatic setting, remains a highly lethal disease. Here we use fresh patient samples that include treatment-naive primary tissue, matched adjacent normal as well collected from patients with bone metastases. Single-cell transcriptomic analysis cells tumors reveals distinct transcriptional signature...
Neuroblastoma is an aggressive pediatric cancer with a high rate of metastasis to the bone marrow. Despite intensive treatments including high-dose chemotherapy, overall survival for children metastatic neuroblastoma remains dismal. Understanding cellular and molecular mechanisms tumor microenvironment crucial developing new therapies improving clinical outcomes. Here, we used single-cell RNA-sequencing characterize immune cell alterations in marrow metastases by comparative analysis...
Androgen deprivation therapy (ADT) plays a central role in the management of men with locally advanced, recurrent, and metastatic prostate cancer. Because most diagnosed cancer will die something other than their cancer, treatment-related adverse effects are highly relevant to long-term health. Benefits ADT each clinical setting must be weighed against ADT-related effects. is detrimental several metabolic end points bone has been prospectively shown cause decreased lean muscle mass,...
Cabozantinib is an oral MET/VEGFR2 inhibitor. A recent phase II study of cabozantinib (100 mg daily) showed improved bone scans in subjects with metastatic castration-resistant prostate cancer (mCRPC), but adverse events (AE) caused frequent dose reductions. This was designed to determine the efficacy and tolerability at lower starting doses.An adaptive design used lowest active daily among 60, 40, 20 mg. The primary endpoint week 6 scan response, defined as ≥30% decrease lesion area....
PURPOSE In 2017, Cancer Care Ontario’s Program in Evidence-Based released the Bone Health and Bone-Targeted Therapies for Prostate guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk nonmetastatic disease to men with castration-resistant cancer metastatic bone. ASCO has policy set procedures endorsing practice guidelines that have been developed by other...
Androgen deprivation therapy (ADT) for prostate cancer causes an increase in fasting insulin and adverse changes body composition serum lipid profile. It is unknown what other metabolic alterations are caused by ADT. To better characterize the effects of ADT, we measured plasma metabolomic profile at baseline after first 3 months therapy.Fasting samples were drawn from 36 subjects gonadotropin releasing hormone (GnRH) agonist therapy. Extracted split into equal parts analysis on gas...
Osteoporosis causes morbidity and mortality in men. The National Foundation recommends fracture risk assessment with the online WHO/FRAX tool. Although androgen deprivation therapy for prostate cancer increases risk, there is limited information about which men require preventative drug therapy. We applied tool to treated cancer.Information was collected from a practice cohort of gonadotropin-releasing hormone agonists, included age, height, weight, history agonist treatment, dual energy...